VILLA GUARDIA, Italy--(BUSINESS WIRE)--Gentium S.p.A (NASDAQ: GENT) (the “Company”) announced today that, as a corollary to its Phase III clinical trial of Defibrotide to treat veno-occlusive disease (“VOD”) with multiple-organ failure (“Severe VOD”), the Company has also instituted an expanded access program for Defibrotide to treat Severe VOD. The initiation of the expanded access program will not impact enrollment in the Company’s Phase III clinical trial as only patients who are not eligible to participate in or otherwise lack access to the Phase III clinical trial will be able to participate in the expanded access program.
